Put Buying Activity in Medifast (MED) Targets Downside in Shares Following Last Week's Earnings Sell-Off -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Medifast (MED) PT Lowered to $155 at Lane Research
November 11, 2019 12:49 PM ESTLane Research analyst Douglas M. Lane lowered the price target on Medifast (NYSE: MED) to $155.00 (from $170.00) while maintaining a Buy rating.
... MorePre-Open Movers 11/08: (DERM) (STMP) (DIS) Higher; (ANAB) (MED) (TDC) Lower (more...)
November 8, 2019 9:23 AM ESTToday's Pre-Open Movers
AnaptysBio, Inc. (Nasdaq: ANAB) 71.9% LOWER; announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis. Each of the etokimab dosing arms failed to meet the primary endpoint of the trial, which was demonstration of statistically greater improvement in the Eczema Area and Severity Index (EASI) relative placebo at week 16. The Company will be receiving... More
UPDATE: DA Davidson Downgrades Medifast (MED) to Neutral; 'Gone Off the Rails'
November 8, 2019 6:37 AM EST(Updated - November 8, 2019 9:38 AM EST)
(updated to add analyst comments)
DA Davidson analyst Linda Bolton Weiser downgraded Medifast (NYSE: MED) from Buy to Neutral with a price target of $74.00 (from $250.00).
The analyst commented, "MED reported disappointing 3Q19 results and... More
After-Hours Movers 11/07: (TRUE) (STMP) (DIS) Higher; (MED) (TDC) (GPS) Lower (more...)
November 7, 2019 6:26 PM ESTToday's After-Hours Movers
Medifast (NYSE: MED) 27.9% HIGHER; reported Q3 EPS of $1.32, $0.02 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $190.1 million versus the consensus estimate of $195.17 million. Medifast sees Q4 2019 EPS of $1.03-$1.13, versus the consensus of $2.05. Medifast sees Q4 2019 revenue of $157-167 million, versus the consensus of $202.33 million.
TrueCar (NASDAQ: TRUE) 25.6% HIGHER; reported Q3 EPS of $0.04, $0.07 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $90.6 million versus the consensus... More
Medifast (MED) Misses Q3 EPS by 2c, Q4 Guidance Falls Well Short of Consensus
November 7, 2019 4:28 PM ESTMedifast (NYSE: MED) reported Q3 EPS of $1.32, $0.02 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $190.1 million versus the consensus estimate of $195.17 million.
GUIDANCE:
Medifast sees Q4 2019 EPS of $1.03-$1.13, versus the consensus of $2.05. Medifast sees Q4... More
